Macmillan: Review of drug information

Macmillan: Review of drug information

BOPA Members – Help required!

Macmillan produces many cancer drug treatment pages. They are widely used by healthcare professionals and people affected by cancer across the UK. We work hard to ensure that they provide the information people need to understand their treatment and ask questions. These online pages also link to other sources of information and support about cancer types, types of treatments, and managing side effects. The information needs to be current, clinically accurate and reflect the real-world patient experience.  We rely on expert speciality pharmacists to review our drug information, and make suggestions, to ensure we have met our goal.

We are always looking for specialist oncology and haematology pharmacists to join our review panel. We ask that our reviewers complete a short survey so that we can capture contact details, specialities and interests in a way that is GDPR compliant. We have a protected database to keep these details secure.

The help can range from looking at a couple of pages once or twice a year, or more if you are able. We are always flexible, you can always say “I am not able to this time” or “yes I can review, if you can give me more time”. We always appreciate that people are kindly giving us their time and expertise and we are very grateful.

We send the pages as Word documents. We ask if you could add comments and/or mark any changes using the ‘Track changes’ facility. Or you may prefer to email us with your comments.
We are generally looking for:

  • Is the information clinically accurate and up-to-date?
  • Are there any issues that you feel we have left out?
  • Is there anything that you think could have been explained more clearly?
  • Feel free to add any other comments that you have.

If you would like to join our professional reviewers or would like to find out more please contact Helen Purdon at [email protected]

Thank you for your ongoing help,
Best wishes,
Helen

Helen Purdon (She/her)
Cancer Information Development Nurse

The below pages are to be reviewed soon:

  • Stilboestrol
  • Palbociclib
  • Ribociclib
  • Doxorubicin
  • Doxorubicin and ifosfamide
  • Gefitinib
  • Midostaurin
  • De Gramont/modified de Gramont
  • Cisplatin and 5FU
  • Leuprorelin
  • CODOX-M
  • Torifemine
  • GemCarbo
  • Crizotinib
  • Rasburicase
  • EPO
  • G-CSF
  • Cabazitaxel
  • TC
  • CVP
  • Bendamustine
  • Encorafenib and binimetinib
  • Mesna

Latest News

By BOPA Committee on 16th May 2024

CRUK Consent Forms – NET and Prostate Cancer Update

The regimen specific consent forms for neuroendocrine and adrenal cancers have been reviewed, updated and added to the CRUK website. In addition, a new consent form for prostate has been…

Read article
By BOPA Research Committee on 15th May 2024

Survey on reach of CRUK SACT regimen-specific consent forms

The national regimen specific consent form project team would like you to complete a short survey to help us to  evaluate the uptake of  the regimen specific SACT consent forms…

Read article
By BOPA Research Committee on 15th May 2024

Survey: Investigating Physical Activity in Advanced Cancer Care

We are looking for healthcare professionals in the UK working with patients with advanced cancer to participate in a 10-minute survey as part of a study. The study titled: “Exploring Oncologists’ and…

Read article
By BOPA E&T Subcommittee on 13th May 2024

BOPA Collaboration Webinar – Highlights from COSA ASM 2023

Tuesday 25th June 2024 at 10:00 BST (19:00 ASET, 03:00 MDT)   The BOPA Education and Training Subcommittee would like to invite you to the next series of three-part collaboration…

Read article